STO · AINO.ST
Aino Health AB (publ)
SEK 0.20SEK 0.00 (0.0%)
Aino Health AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 20.0% below the high.
Loading market information…
STO · EPIS-B.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Episurf Medical AB’s quoted price sits in the lower half of its reported 52-week range, 79.55% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Episurf Medical AB’s next earnings report is currently expected on Nov 20, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Episurf Medical AB’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Episurf Medical AB (publ), a medical device company, designs and manufactures implants and surgical instruments in Germany, Sweden, rest of Europe, the United States, and internationally. It provides Episealer Knee for repairing focal cartilage and bone defects to reduce pain and increase mobility in the patient’s knee joint; Episealer implant, which is designed to fit anatomy and size of the lesion; Episealer toolkit; and Episealer Patellofemoral System, a system to treat osteoarthritis limited to the patellofemoral part of the knee joint. The company also offers Epioscopy to identify and visualize femoral knee joint cartilage and bone lesions, and tibia, as well as defects on the cruciate ligaments and menisci; Epiguide, a surgical drill guide; and µiFidelity, a web platform for order management, communication, personalized design, and surgical pre-planning. In addition, it is developing Episealer MTP implant, an implant for the MTP joint of the big toe in the foot. Further, the company offers Talus Osteotomy Guide (TOG) that is designed to fit on the patient’s distal tibia using CT and MRI images; MRI protocol to ensure correct damage assessment, 3D visualization, and device design; and Damage Marking Report (DMR) that enables 3D visualization of damage in the joint surface and underlaying bone defects, as well as other findings relevant when selecting the right treatment for the patient. The company was formerly known as Diamorph Medtech AB and changed its name to Episurf Medical AB (publ) in 2010. Episurf Medical AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:57 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Feb 6, 2025 |
| -SEK 0.03 |
| SEK 3.40M-2.86% vs estimate |
| Q3 2024 | Oct 25, 2024 | -SEK 0.02 | SEK 3.40M-44.26% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 0.20SEK 0.00 (0.0%)
Aino Health AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 20.0% below the high.
SEK 0.01+SEK 0.00 (+6.98%)
Spermosens AB’s quoted price sits in the upper half of its reported 52-week range, 23.33% below the high.
SEK 1.10+SEK 0.07 (+6.6%)
Qlife Holding AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 71.11% below the high.
SEK 1.47SEK 0.00 (0.0%)
Guard Therapeutics International AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 94.56% below the high.
SEK 1.33-SEK 0.04 (-2.92%)
ODI Pharma AB’s quoted price sits in the lower half of its reported 52-week range, 75.6% below the high.
SEK 0.18-SEK 0.01 (-3.19%)
Modus Therapeutics Holding AB’s quoted price sits in the lower half of its reported 52-week range, 69.46% below the high.
SEK 0.42-SEK 0.06 (-12.13%)
2cureX AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 87.16% below the high.
SEK 0.11+SEK 0.00 (0.0%)
Prostatype Genomics AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 95.31% below the high.
